Current Urology Reports

, 19:64 | Cite as

Ureteral Stent Discomfort and Its Management

  • Katherine M. Fischer
  • Michael Louie
  • Phillip MucksavageEmail author
Endourology (P Mucksavage, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Endourology


Purpose of Review

Ureteral stent placement is a very common urologic procedure and a necessary component of many minimally invasive surgeries including ureteroscopy. Despite its widespread use, stent placement results in bothersome urinary symptoms and pain in approximately 80% of patients. This review discusses the proposed mechanisms underlying ureteral stent-related symptoms and current approaches to symptom management and the evidence to support them.

Recent Findings

Though it has been extensively studied, the exact cause of stent-related symptoms remains unknown but is likely related to irritation of the bladder by the distal curl of the stent and reflux of urine through the stent up to the renal pelvis and transmission of high pressures associated with this. Recent research has focused on trying to modify stents including the creation of drug eluting stents as well as preventing symptoms with intravesical instillation of medications in the operative room at the time of placement. Some of these approaches show promise, but anticholinergic and alpha-blocking medications remain the only treatments for stent-related symptoms with reasonable evidence to support them.


Current evidence suggests that a multimodal approach to stent-related symptoms and pain with alpha-blockers, anticholinergic medications, and anti-inflammatory and narcotic pain medications is likely the most effective. Further research is needed to better investigate many novel techniques for decreasing stent-related symptoms. This continues to be an important area of research given the need for ureteral stents in urology and the high prevalence of patient discomfort related to stent placement.


Ureteral stent Stent-related pain Stent-related voiding symptoms 


Compliance with Ethical Standards

Conflict of Interest

Katherine M. Fischer and Michael Louie each declare no potential conflicts of interest.

Phillip Mucksavage is a section editor for Current Urology Reports.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Finney RP. Experience with new double J ureteral catheter stent. J Urol. 1978;120:678–81.CrossRefPubMedGoogle Scholar
  2. 2.
    Joshi HB, Okeke A, Newns N, Keeley FX Jr, Timoney AG. Characterization of urinary symptoms in patients with ureteral stents. Urology. 2002;59(4):511–6.CrossRefPubMedGoogle Scholar
  3. 3.
    Joshi HB, Stainthorpe A, Keeley FX Jr, MacDonagh R, Timoney AG. Indwelling ureteral stents: evaluation of quality of life to aid outcome analysis. J Endourol. 2001;15(2):151–4.CrossRefPubMedGoogle Scholar
  4. 4.
    • Joshi HB, et al. Ureteral stent symptom questionnaire: development and validation of a multidimensional quality of life measure. J Urol. 2003;169(3):1060–4. The ureteral stent symptoms questionnaire (USSQ) described and validated in this paper is the only validated measure to study specifically stent-related symptoms. This measure is used by most groups investigating therapies to improve stent-related symptoms and is therefore important to be familiar with and understand. CrossRefPubMedGoogle Scholar
  5. 5.
    Miyaoka R, Monga M. Ureteral stent discomfort: etiology and management. Indian Journal of Urology: IJU: Journal of the Urological Society of India. 2009;25(4):455–60. CrossRefGoogle Scholar
  6. 6.
    Chew BH, Knudsen BH, Denstedt D. The use of stents in contemporary urology. Curr Opin Urol. 2004;14:111–5.CrossRefPubMedGoogle Scholar
  7. 7.
    Haleblian G, Kijvikain K, de la Rosette J, Preminger G. Ureteral stenting and urinary stone management: a systematic review. J Urol. 2008;179:424–30.CrossRefPubMedGoogle Scholar
  8. 8.
    Thomas R. Indwelling ureteral stents: impact of material and shape on patient comfort. J Endourol. 1993;7(2):137–40.CrossRefPubMedGoogle Scholar
  9. 9.
    Joshi HB, Stainthorpe A, MacDonagh R, Keeley FX Jr, Timoney AG, Barry MJ. Indwelling ureteral stents: evaluation of symptoms, quality of life and utility. J Urol. 2003;169(3):1065–9; discussion–9.CrossRefPubMedGoogle Scholar
  10. 10.
    Ramsay JW, et al. The effects of double J stenting on unobstructed ureters. An experimental and clinical study. Br J Urol. 1985;57(6):630–4.CrossRefPubMedGoogle Scholar
  11. 11.
    Mosli HA, Farsi HMA, al-Zimaity MF, Saleh TR, al-Zamzami MM. Vesicoureteral reflux in patients with double pigtail stents. J Urol. 1991;146(4):966–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Chew BH, Knudsen BE, Nott L, Pautler SE, Razvi H, Amann J, et al. Pilot study of ureteral movement in stented patients: first step in understanding dynamic ureteral anatomy to improve stent comfort. J Endourol. 2007;21(9):1069–75.CrossRefPubMedGoogle Scholar
  13. 13.
    Rane A, Saleemi A, Cahill D, Sriprasad S, Shrotri N, Tiptaft R. Have stent-related symptoms anything to do with placement technique? J Endourol. 2001;15(7):741–5.CrossRefPubMedGoogle Scholar
  14. 14.
    Al-Kandari AM, et al. Effects of proximal and distal ends of double-J ureteral stent position on postprocedural symptoms and quality of life: a randomized clinical trial. J Endourol. 2007;21(7):698–702.CrossRefPubMedGoogle Scholar
  15. 15.
    Ho CH, Chen SC, Chung SD, Lee YJ, Chen J, Yu HJ, et al. Determining the appropriate length of a double-pigtail ureteral stent by both stent configurations and related symptoms. J Endourol. 2008;22(7):1427–31.CrossRefPubMedGoogle Scholar
  16. 16.
    El-Nahas AR, et al. Self-retaining ureteral stents: analysis of factors responsible for patients’ discomfort. J Endourol. 2006;20(1):33–7.CrossRefPubMedGoogle Scholar
  17. 17.
    Giannarini G, Keeley Jr FX, Valent F, Manassero F, Mogorovich A, Autorino R, et al. Predictors of morbidity in patients with indwelling ureteric stents: results of a prospective study using the validated ureteric stent symptoms questionnaire. BJU Int. 2011;107(4):648–54.CrossRefPubMedGoogle Scholar
  18. 18.
    Damiano R, Autorino R, de Sio M, Cantiello F, Quarto G, Perdonà S, et al. Does the size of ureteral stent impact urinary symptoms and quality of life? A prospective randomized study. Eur Urol. 2005;48(4):673–8.CrossRefPubMedGoogle Scholar
  19. 19.
    Candela JV, Bellman GC. Ureteral stents: impact of diameter and composition on patient symptoms. J Endourol. 1997;11(1):45–7.CrossRefPubMedGoogle Scholar
  20. 20.
    Erturk E, Sessions A, Joseph JV. Impact of ureteral stent diameter on symptoms and tolerability. J Endourol. 2003;17(2):59–62.CrossRefPubMedGoogle Scholar
  21. 21.
    Liu S, Yu Y, Gao Y, Yang X, Pang Z. Decreased urinary glycosaminoglycan excretion following alfuzosin treatment on ureteral stent-related symptoms: a prospective, randomized, placebo-controlled study. Urolithiasis. 2016;44(2):185–90.CrossRefPubMedGoogle Scholar
  22. 22.
    Assimos D, et al. Surgical management of stones: American urological association/endourological society guideline. J Urol. 2016;196(4):1161–9.CrossRefPubMedGoogle Scholar
  23. 23.
    Taguchi M, Yoshida K, Sugi M, Matsuda T, Kinoshita H. A ureteral stent crossing the bladder midline leads to worse urinary symptoms. Central European Journal of Urology. 2017;70(4):412–7.PubMedPubMedCentralGoogle Scholar
  24. 24.
    Abt D, Mordasini L, Warzinek E, Schmid HP, Haile SR, Engeler DS, et al. Is intravesical stent position a predictor of associated morbidity? Korean Journal of Urology. 2015;56(5):370–8.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Lee C, Kuskowski M, Premoli J, Skemp N, Monga M. Randomized evaluation of ureteral stents using validated symptom questionnaire. J Endourol. 2005;19(8):990–3.CrossRefPubMedGoogle Scholar
  26. 26.
    Lennon GM, Thornhill JA, Sweeney PA, Grainger R, McDermott TED, Butler MR. ‘Firm’ versus ‘soft’ double pigtail ureteric stents: a randomised blind comparative trial. Eur Urol. 1995;28(1):1–5.CrossRefPubMedGoogle Scholar
  27. 27.
    Park HK, Paick SH, Kim HG, Lho YS, Bae S. The impact of ureteral stent type on patient symptoms as determined by the ureteral stent symptom questionnaire: a prospective, randomized, controlled study. J Endourol. 2015;29(3):367–71.CrossRefPubMedGoogle Scholar
  28. 28.
    Lee JN, Kim BS. Comparison of efficacy and bladder irritation symptoms among three different ureteral stents: a double-blind, prospective, randomized controlled trial. Scandinavian Journal of Urology. 2015;49(3):237–41.CrossRefPubMedGoogle Scholar
  29. 29.
    Taguchi M, Inoue T, Muguruma K, Murota T, Kinoshita H, Matsuda T. Impact of loop-tail ureteral stents on ureteral stent-related symptoms immediately after ureteroscopic lithotripsy: comparison with pigtail ureteral stents. Investigative and clinical urology. 2017;58(6):440–6.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Beiko DT, Watterson JD, Knudsen BE, Nott L, Pautler SE, Brock GB, et al. Double-blind randomized controlled trial assessing the safety and efficacy of intravesical agents for ureteral stent symptoms after extracorporeal shockwave lithotripsy. J Endourol. 2004;18(8):723–30.CrossRefPubMedGoogle Scholar
  31. 31.
    Roberts G, Leslie R, Robb S, Siemens DR, Beiko D. Intraureteral lidocaine for ureteral stent symptoms post-ureteroscopy: a randomized, phase 2, placebo-controlled trial. Canadian Urological Association Journal. 2017;11(10):326–30.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Gupta M, Patel T, Xavier K, Maruffo F, Lehman D, Walsh R, et al. Prospective randomized evaluation of periureteral botulinum toxin type A injection for ureteral stent pain reduction. J Urol. 2010;183(2):598–602.CrossRefPubMedGoogle Scholar
  33. 33.
    Sur RL, Haleblian GE, Cantor DA, Springhart WP, Albala DM, Preminger GM. Efficacy of intravesical ropivacaine injection on urinary symptoms following ureteral stenting: a randomized, controlled study. J Endourol. 2008;22(3):473–8.CrossRefPubMedGoogle Scholar
  34. 34.
    Mendez-Probst CE, Goneau LW, MacDonald KW, Nott L, Seney S, Elwood CN, et al. The use of triclosan eluting stents effectively reduces ureteral stent symptoms: a prospectiverandomized trial. BJU Int. 2012;110:749–54.CrossRefPubMedGoogle Scholar
  35. 35.
    Krambeck AE, Walsh RS, Denstedt JD, Preminger GM, Li J, Evans JC, et al. A novel drug eluting ureteral stent: a prospective, randomized, multicenter clinical trial to evaluate the safety and effectiveness of a ketorolac loaded ureteral stent. J Urol. 2010;183:1037–42.CrossRefPubMedGoogle Scholar
  36. 36.
    Lee FC, Holt SK, Hsi RS, Haynes BM, Harper JD. Preoperative belladonna and opium suppository for ureteral stent pain: a randomized, double-blinded, placebo-controlled study. Urology. 2017;100:27–32.CrossRefPubMedGoogle Scholar
  37. 37.
    •• Koprowski C, Kim C, Modi PK, Elsamra SE. Ureteral stent-associated pain: a review. J Endourol. 2016;30(7):744–53. A good, recent review of factors associated with stent-related pain and the proposed mechanisms of stent-related symptoms. CrossRefPubMedGoogle Scholar
  38. 38.
    Lamb AD, Vowler SL, Johnston R, Dunn N, Wiseman OJ. Meta-analysis showing the beneficial effect of alpha-blockers on ureteric stent discomfort. BJU Int. 2011;108(11):1894–902.CrossRefPubMedGoogle Scholar
  39. 39.
    Kwon JK, Cho KS, Oh CK, Kang DH, Lee H, Ham WS, et al. The beneficial effect of alpha-blockers for ureteral stent-related discomfort: systematic review and network meta-analysis for alfuzosin versus tamsulosin versus placebo. BMC Urol. 2015;15(1):55.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Lee YJ, Huang KH, Yang HJ, Chang HC, Chen J, Yang TK. Solifenacin improves double-J stent-related symptoms in both genders following uncomplicated ureteroscopic lithotripsy. Urolithiasis. 2013;41:247–52.CrossRefPubMedGoogle Scholar
  41. 41.
    Abdelhamid MH, Zayed AS, Ghoneima WE, Elmarakbi AA, el Sheemy MS, Aref A, et al. Randomized, double-blind, placebo-controlled trial to compare solifenacin versus trospium chloride in the relief of double-J stent-related symptoms. World J Urol. 2017;35(8):1261–8.CrossRefPubMedGoogle Scholar
  42. 42.
    El-nahas AR, Tharwat M, Elsaadany M, Mosbah A, Gaballah MA. A randomized controlled trial comparing alpha blocker (tamsulosin) and anticholinergic (solifenacin) in treatment of ureteral stent-related symptoms. World J Urol. 2016;34(7):963–8.CrossRefPubMedGoogle Scholar
  43. 43.
    •• Zhou L, Cai X, Li H, Wang KJ. Effects of α-blockers, antimuscarinics, or combination therapy in relieving ureteral stent-related symptoms: a meta-analysis. J Endourol. 2015;29:650. This meta-analysis found that both anticholinergics and alpha-blockers decrease stent discomfort with the combination of both types of medications being superior to monotherapy.–6.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Zhang YM, Chu P, Wang WJ. PRISMA-combined α-blockers and antimuscarinics for ureteral stent-related symptoms: a meta-analysis. Medicine. 2017;96(7)Google Scholar
  45. 45.
    Yan H, Wang Y, Sun R, Cui Y. The efficacy of antimuscarinics alone or in combination with alpha-blockers for the treatment of ureteral stent-related symptoms: a systematic review and meta-analysis. Urol Int. 2017;99(1):6–13.CrossRefPubMedGoogle Scholar
  46. 46.
    Norris RD, Sur RL, Springhart WP, Marguet CG, Mathias BJ, Pietrow PK, et al. A prospective, randomized, double-blinded placebo-controlled comparison of extended release oxybutynin versus phenazopyridine for the management of postoperative ureteral stent discomfort. Urology. 2008;71(5):792–5.CrossRefPubMedGoogle Scholar
  47. 47.
    Tadros NN, Bland L, Legg E, Olyaei A, Conlin MJ. A single dose of a non-steroidal anti-inflammatory drug (NSAID) prevents severe pain after ureteric stent removal: a prospective, randomised, double-blind, placebo-controlled trial. BJU Int. 2013;111:101–5.CrossRefPubMedGoogle Scholar
  48. 48.
    Ragab M, Soliman MG, Tawfik A, Abdel Raheem A, el-Tatawy H, Abo Farha M, et al. The role of pregabalin in relieving ureteral stent-related symptoms: a randomized controlled clinical trial. Int Urol Nephrol. 2017;49(6):961–6.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Katherine M. Fischer
    • 1
  • Michael Louie
    • 2
  • Phillip Mucksavage
    • 1
    Email author
  1. 1.Department of UrologyHospital of the University of PennsylvaniaPhiladelphiaUSA
  2. 2.Department of UrologyUniversity of California Irvine HealthIrvineUSA

Personalised recommendations